<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">Regarding antibodies, plasma therapy using convalescent plasma from fully recovered patients is effective against these coronaviruses, including SARS-CoV-2.
 <sup>
  <xref ref-type="bibr" rid="CR108">108</xref>,
  <xref ref-type="bibr" rid="CR130">130</xref>
 </sup> Tocilizumab (anti-human IL-6 receptor) may curb immunopathology and trials are ongoing now.
 <sup>
  <xref ref-type="bibr" rid="CR131">131</xref>
 </sup> A study of novel monoclonal antibodies against the MERS-CoV spike protein suggests that mAbs can be utilized for the identification of specific mutations of MERS-CoV.
 <sup>
  <xref ref-type="bibr" rid="CR132">132</xref>
 </sup> Wang et al. provided an all-hydrocarbon-stapled peptide that likely mimics the native conformation of the C-terminal short Î±-helical region of the MERS-CoV S protein, which can block the formation of the hexameric coiled-coil fusion complex to inhibit viral-cell membrane fusion.
 <sup>
  <xref ref-type="bibr" rid="CR133">133</xref>,
  <xref ref-type="bibr" rid="CR134">134</xref>
 </sup>
</p>
